Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics


Cumberland Pharmaceuticals Inc. (CPIX)

Today's Latest Price: $3.24 USD

0.01 (-0.31%)

Updated Jan 15 3:59pm

Add CPIX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CPIX Stock Summary

  • With a market capitalization of $49,200,525, Cumberland Pharmaceuticals Inc has a greater market value than only 10.87% of US stocks.
  • In terms of volatility of its share price, CPIX is more volatile than just 15% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CPIX comes in at 11.08% -- higher than that of 84.33% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cumberland Pharmaceuticals Inc are BLIN, DOGZ, NSPR, FEIM, and OBLG.
  • CPIX's SEC filings can be seen here. And to visit Cumberland Pharmaceuticals Inc's official web site, go to www.cumberlandpharma.com.

CPIX Stock Price Chart Interactive Chart >

Price chart for CPIX

CPIX Price/Volume Stats

Current price $3.24 52-week high $5.23
Prev. close $3.25 52-week low $2.77
Day low $3.22 Volume 18,600
Day high $3.28 Avg. volume 21,380
50-day MA $3.02 Dividend yield N/A
200-day MA $3.30 Market Cap 48.66M

Cumberland Pharmaceuticals Inc. (CPIX) Company Bio


Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.

CPIX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.24$1.09 -66%

Below please find a table outlining a discounted cash flow forecast for CPIX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 72. Its equity weight surpasses that of only 23.83% of free cash flow generating stocks in the Healthcare sector.
  • Cumberland Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -12.15. This coverage rate is greater than that of merely 7.05% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-67%
1%-67%
2%-66%
3%-66%
4%-66%
5%-65%

ABC, EDAP, WST, ABT, and AZN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


CPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPIX Latest Social Stream


Loading social stream, please wait...

View Full CPIX Social Stream

Latest CPIX News From Around the Web

Below are the latest news stories about Cumberland Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPIX as an investment opportunity.

Where Do Hedge Funds Stand On Cumberland Pharmaceuticals, Inc. (CPIX)?

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Yahoo | November 27, 2020

Cumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update

NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 million….

PR Newswire | November 10, 2020

Cumberland's Earnings: A Preview

Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Analysts covering Cumberland have modeled for quarterly EPS loss of $0.07 on revenue of $8.61 million. In the same quarter last year, Cumberland reported EPS of $0.01 on revenue of $10.37 million.Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish ...

Yahoo | November 9, 2020

Intravenous (IV) Ibuprofen Market To See Record Break Revenue $14.2 Million By 2022 | Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc.

UPDATE AVAILABLE ON-DEMAND According to the research report published by Allied Market Research, the global Intravenous (IV) Ibuprofen market is expected to register a CAGR of 20.0% from 2016 to 2022. The research includes changing market dynamics, top impacting factors, key

OpenPR | October 5, 2020

Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use

NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…

PR Newswire | August 18, 2020

Read More 'CPIX' Stories Here

CPIX Price Returns

1-mo 5.19%
3-mo 9.09%
6-mo 0.62%
1-year -36.47%
3-year -53.91%
5-year -34.68%
YTD 9.83%
2020 -42.72%
2019 -14.59%
2018 -18.07%
2017 33.82%
2016 4.56%

Continue Researching CPIX

Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:

Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.976 seconds.